



Ref: Syn/CS/SE/PR/July-009

Syngene International Limited

Biocon Park SEZ, Bommasandra IV Phase
Jigani Link Road, Bangalore 560099, India
T +91 80 6775 8000
F +91 80 6775 8808
CIN: L85110KA1993PLC014937

www.syngeneintl.com

July 27, 2017

To, The Manager Listing BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268	To, The Manager Listing National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
-----------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Press Release

This has reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Please find enclosed the press release titled **“Syngene International Announces Broadening of Research Collaboration with Amgen Inc.”**

The above mentioned press release will also be available on website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Mayank Verma

Company Secretary

E: Mayank.verma@syngeneintl.com

M: +91 97399 04949

T: + 91 80 6775 8781

Enclosed: Press Release

Syngene International Announces Broadening of Research Collaboration with Amgen Inc.

Expands Dedicated R&D Center

27 July, 2017, Bangalore, India

Syngene International, India's largest contract research organization, today announced the expansion of its ongoing research collaboration with Amgen Inc. As a result, Syngene will expand the Syngene Amgen Research & Development Center (SARC) in terms of size and scope of its operations.

SARC, the 25,000 sq. ft dedicated R&D Center for Amgen, was established in 2016 in Bangalore, India. It currently has a team of approximately 100 highly qualified Syngene scientists working closely with Amgen researchers around the world on the discovery and development of innovative medicines.

With the expansion, the floor space of SARC will double to 50,000 sq. ft. A team of up to 185 multi-disciplinary Syngene scientists will work at SARC in the areas of medicinal and process chemistry, biologics, bioprocess development, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development.

Commenting on the expansion, Jonathan Hunt, Chief Executive Officer, Syngene International, said, "We are delighted with the expansion of our research collaboration with Amgen. This expansion underscores Syngene's capabilities to execute complex integrated discovery and development projects for Amgen. We are committed to working closely with Amgen's global scientific teams and look forward to SARC playing an increasingly important role in supporting their R&D activities that could benefit patients worldwide."

PRESS RELEASE

The expansion of SARC will be customized to meet Amgen's functional requirements and will include a range of environment-friendly features that will enable optimal utilization of the laboratory space.

About Syngene

Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is India's largest Contract Research Organization providing integrated discovery and development services for novel molecules across multiple platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides. It brings together a state-of-the-art infrastructure spread across 1.3 Mn sq. ft and a highly experienced team of about 3100 scientists, to help R&D focused organizations achieve better R&D efficiency and reduce development time. In FY2017, Syngene serviced 293 clients including 8 of the top 10 global pharma companies as well as industry leaders in segments like biotechnology, nutrition, animal health, consumer goods and specialty chemicals. For more details, visit www.syngeneintl.com.

For further information, please reach out to:

Investor Contact	Media Contact
Chanderlekha Nayar P: +91 80 6775 8821 M: +91 72591 92001 Fax: +91 80 2852 3423 E: chanderlekha.nayar@syngeneintl.com	Sandeep Nair P: +91 80 2808 5476 M: +91 88843 67776 Fax: +91 80 2852 3423 E: sandeep.nair@syngeneintl.com